The possibility for the patent owner to prevent the reimbursement of medicinal products before expiry of patent protection is still an open issue. While the law covers prohibition of reimbursement for medicinal generic...more
The Board of Appeal of the Italian Patent Office (Commissione dei Ricorsi), by decision published on June 26, 2017, acknowledged the right of the patent holder to ask the Italian Patent Office for the limitation of the...more
7/10/2017
/ Appeals ,
Direct Marketing Association ,
EU ,
European Court of Justice (ECJ) ,
European Medicines Agency (EMA) ,
Generic Drugs ,
Intellectual Property Protection ,
Italy ,
Patents ,
Pharmaceutical Industry ,
Prescription Drugs ,
Supplementary Protection Certificate
By order issued on June 18, 2017, in summary proceedings brought by Teva against Mylan and Synthon for the alleged infringement of EP 2 361 924 (covering a manufacturing process for the active ingredient glatiramer acetate),...more
6/23/2017
/ Drug Pricing ,
Generic Drugs ,
Italy ,
Mylan Pharmaceuticals ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Reimbursements ,
Teva Pharmaceuticals
By judgement of January 3rd, 2017, the Turin Court of Appeal delivered a monumental decision in a longstanding patent dispute concerning the validity and infringement of patents relating to an Electronic Program Guide (EPG)...more
2/6/2017
/ Appeals ,
Digital Goods ,
Digital Services ,
EU ,
Infringement ,
Intellectual Property Protection ,
Italy ,
Patent Infringement ,
Patent-Eligible Subject Matter ,
Patents ,
Satellites ,
Software Patents ,
Technology ,
Technology Sector ,
Television Programming